The Evolution of Prodrug Strategies: From Simple Carriers to Smart, Targeted Systems

Prodrugs are pharmacologically inactive compounds designed to undergo biotransformation within the body to release active therapeutic agent. This strategic approach has become increasingly important in overcoming the limitations of conventional drugs, such as poor aqueous solubility, low bioavailability, rapid metabolism, and lack of site specificity. Prodrugs are broadly classified into carrier-linked and bio precursor, each offering unique mechanisms to optimize drug delivery and performance. The review explores historical milestones, key classification systems, and various activation mechanisms involved in prodrug activation. It also highlights modern advancements such as enzyme-targeted prodrugs and nanocarrier systems that improve targeting and reduce systemic side effects. By integrating chemical innovation with biological insights, prodrugs offer a versatile platform for enhancing therapeutic efficacy and patient compliance. This paper presents a comprehensive overview of the design strategies, challenges, and therapeutic applications of prodrugs, reflecting their growing significance in modern drug development and targeted therapy.